NuCana PLC (NASDAQ:NCNA) – Equities research analysts at Jefferies Group increased their FY2017 earnings per share estimates for NuCana in a research note issued to investors on Thursday. Jefferies Group analyst E. Yang now forecasts that the company will earn ($0.15) per share for the year, up from their prior estimate of ($0.20). Jefferies Group currently has a “Buy” rating and a $25.00 target price on the stock. Jefferies Group also issued estimates for NuCana’s Q4 2017 earnings at ($0.12) EPS, Q1 2018 earnings at ($0.14) EPS, Q2 2018 earnings at ($0.22) EPS, Q3 2018 earnings at ($0.31) EPS, Q4 2018 earnings at ($0.41) EPS, FY2018 earnings at ($1.08) EPS, FY2019 earnings at ($1.61) EPS, FY2020 earnings at ($1.14) EPS and FY2021 earnings at $2.14 EPS.

Several other brokerages have also commented on NCNA. Cowen started coverage on shares of NuCana in a research note on Monday, October 23rd. They issued an “outperform” rating on the stock. William Blair started coverage on shares of NuCana in a research note on Monday, October 23rd. They issued an “outperform” rating on the stock. Citigroup started coverage on shares of NuCana in a research note on Monday, October 23rd. They issued a “buy” rating and a $23.00 price target on the stock. Finally, Zacks Investment Research upgraded shares of NuCana from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Tuesday. Five equities research analysts have rated the stock with a buy rating, NuCana has a consensus rating of “Buy” and a consensus target price of $20.00.

Shares of NuCana (NCNA) opened at $10.58 on Monday. NuCana has a 12 month low of $9.64 and a 12 month high of $19.95. The company has a market cap of $335.96 and a P/E ratio of -33.06.

Large investors have recently made changes to their positions in the business. Baillie Gifford & Co. acquired a new position in shares of NuCana during the third quarter valued at approximately $8,266,000. Sphera Funds Management LTD. acquired a new position in shares of NuCana during the third quarter valued at approximately $919,000. Perceptive Advisors LLC acquired a new position in shares of NuCana during the third quarter valued at approximately $3,674,000. Citadel Advisors LLC acquired a new position in shares of NuCana during the third quarter valued at approximately $1,218,000. Finally, Alyeska Investment Group L.P. acquired a new position in shares of NuCana during the third quarter valued at approximately $2,296,000. Institutional investors own 22.27% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Research Analysts Issue Forecasts for NuCana PLC’s FY2017 Earnings (NCNA)” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://theolympiareport.com/2017/12/26/research-analysts-issue-forecasts-for-nucana-plcs-fy2017-earnings-ncna.html.

About NuCana

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Earnings History and Estimates for NuCana (NASDAQ:NCNA)

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.